Menu Search
Equities

Schrodinger Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
43Z:STU

Schrodinger Inc

Actions
  • Price (EUR)9.51
  • Today's Change-0.466 / -4.67%
  • Shares traded1.00k
  • 1 Year change-58.82%
  • Beta1.5858
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

  • Revenue in USD (TTM)256.95m
  • Net income in USD-175.99m
  • Incorporated1995
  • Employees891.00
  • Location
    Schrodinger Inc1540 BROADWAY, 24TH FLOORNEW YORK 10036United StatesUSA
  • Phone+1 (503) 299-1150
  • Fax+1 (302) 655-5049
  • Websitehttps://www.schrodinger.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.